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INTRODUCTION
Much has been written about 'innovation' in
excipients. Materials that are primarily
manufactured for the food or cosmetic industry
can be combined together or derivatised further
in various permutations to impart improved
properties/functionality to existing materials
and/or their combinations, to achieve less
excipient variability and to increase excipient
understanding (see Figure 1). The approach of
mixing and/or derivatizing food ingredients
improves manufacturing efficiencies without
getting bogged down in the morass of
governmental regulation, and imparts
synergistic functional properties to existing
materials. 
The current generation of combined or
derivatized excipients primarily increase
manufacturing efficiencies,  improve API
ADME profiles and provide sustained delivery.
While these attributes certainly are by no means
trivial for the pharmaceutical industry, they are
not necessarily conducive to enable in vivo
delivery or increase in vivo efficacy of next
generation APIs’, which may be defined as
consisting of oligopeptides, peptides and gene
modulation/delivery components. It may very
well be that these are the only attributes that the
current food ingredient combinations can
change without surfacing on the regulatory
radar. On the other hand, it is also possible that
some derivatized food ingredients may
serendipitiously affect such attributes.  A
prominent example is the discovery that
polyoxyethylated castor oil derivatives (and
subsequent l y ,  the  po lyoxye thy lene-
polyoxypropylene block polymers) could
modulate cellular efflux pump function. While
the ability of food ingredient mixtures or
derivatives to modulate more of such ‘delivery
attributes' should not be underestimated, a re-
evaluation of this paradigm is necessary such
that 'innovation by design' supersedes
'innovation by serendipity', especially with
regard to making pharmaceutical excipients fit
for in vivo purpose.
Innovation in pharmaceutical ingredients could
include prospective design (rather than
retrospective discovery) of excipient molecules
that actively or passively facilitate the targeted
drug delivery of next generation APIs’.   For
example, such excipients could be designed to
possess attributes that modulate cell and/or
nuclear permeability, efflux pumps, cytochrome
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Figure 1 Pharmaceutical excipients as offshoots of the food/cosmetic industry.
P450 enzymes, receptor engagement/
internalization and in vivo targetability. In vivo fit
for purpose excipients would enable oral
delivery of high molecular weight protein APIs',
thermostabilize vaccine products, provide
acceptable serum stability (especially for non-
glycosylated peptides), suppress API
stimulation of innate immune responses and
facilitate gene transduction in non-dividing,
quiescent cells. Such innovative attributes
would also include minimization of API off-
target effects and circumventing the so called
'first pass' phenomenon which is characteristic
of many protein or nucleic acid API loaded
liposomes or nanoparticles. This is especially
important because APIs' that rely on cellular
processing to exert their therapeutic effect
(siRNA for example) have been shown to
saturate such pathways at higher concentrations
leading to significant morbidity. Dose
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minimization is critical toward favorable clinical
outcomes. The lack of these attributes  signify
significant unmet medical needs especially when
the 'next generation' of high molecular weight
protein, nucleic acid or gene therapies is
considered.
Perhaps this is asking too much of molecules
that were originally defined as 'inactive
ingredients'. Perhaps such 'enabling' attributes
are better endowed to APIs' themselves via
modification of their structures (PEGylation or
conjugation). Perhaps such an approach blurs
the distinction between an API and an excipient
to an unacceptable degree. However, a mere
acknowledgment that such in vivo fit for
purpose molecules can be designated as
excipients (under carefully formulated
considerations); and that they can be approved
as 'stand alone' entities (with a clear and
coherent regulatory pathway); will enable
rational design of excipient molecules
possessing intricate, defined and built in in vivo
mechanisms. Their 'innovative attributes' can
then complement individual next generation
API's to deliver favorable clinical outcomes.
Some examples of such molecules may include
ligands for specific receptors, cell penetrating
peptides, individual lipid or protein molecules
making up exosomes or exosome mimetics,
endosome or lysosome destabilizers such as
bacterial porins, transfection enhancers
including Gemini surfactants, subcellular
and/or  ves i c l e  t r a f f i c  modu la t ing
excipients/proteins and polyamidoamine
PAMAM dendrimers.
Given the regulatory constraints that
pharmaceutical excipient manufacturers operate
under a.k.a. the absence of a regulatory path
toward approval of 'stand alone' new excipients,
the current paradigm of food ingredient 'mixing
and matching' and derivatization and siphoning
more succedants from the food industry seems
to be the only sustainable business model. With
few exceptions, funding, capital expenditure
and research on excipients focused on
improving clinical outcomes with difficult to
deliver next generation APIs’ is mostly non-
existent. While it is implicitly recognized that
some currently available excipients coincidently
increase efficacy and targetability of some API
formulations because of their in vivo attribute
modulating properties, there seems to be no
sense of urgency to explicitly accept and
regulate intentionally designed, fit for in vivo
purpose, excipients. There needs to be
recognition that excipient functionality
encompasses not only manufacturability and
marketability, but also in vivo attributes such as
facilitation of targetability and increase of
efficacy, especially of next generation APIs'. 
Innovation in excipients can address excipient
functionality, variability and understanding.
Another aspect of such innovation could
encompass excipients that are deliberately
designed to make them fit for in vivo purpose, to
facilitate cellular (and sub-cellular) specific
delivery of next generation API’s that require
such exquisite targeted delivery in order  to  be
efficacious and safe. 
To quote from Thoreau's Walden, “...The man
who goes alone can start today; but he who
travels with another must wait till that other is
ready”. It seems high time that the current
regulatory paradigm of  approving excipients,
only as part of a medicinal product, was re-
evaluated; and reformulated to approve 'stand
alone' excipients. The APIs' are waiting.
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